Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant humanized (from mouse) antibody expressed in CHO binding to human CD74. Milatuzumab is a monoclonal antibody for the treatment of multiple myeloma and other hematological malignancies.
IgG1 - kappa
The details of the immunogen for this antibody are not available.
Suitable for use in Neut, ELISA, IF, IP, FuncS, FC, ICC and most other immunological methods.
Predicted N terminal
>95.0%, determined by analysis by RP-HPLC & analysis by SDS-PAGE.
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Milatuzumab is a monoclonal antibody for the treatment of multiple myeloma and other hematological malignancies.
The protein encoded by this gene associates with class II major histocompatibility complex (MHC) and is an important chaperone that regulates antigen presentation for immune response. It also serves as cell surface receptor for the cytokine macrophage migration inhibitory factor (MIF) which, when bound to the encoded protein, initiates survival pathways and cell proliferation. This protein also interacts with amyloid precursor protein (APP) and suppresses the production of amyloid beta (Abeta). Multiple alternatively spliced transcript variants encoding different isoforms have been identified.
MHC class II protein binding; MHC class II protein binding; beta-amyloid binding; cytokine binding; cytokine receptor activity; identical protein binding; nitric-oxide synthase binding;
CD74; CD74 molecule, major histocompatibility complex, class II invariant chain; CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen associated) , DHLAG; HLA class II histocompatibility antigen gamma chain; gamma chain of class II antigens; HLA DR gamma; Ia associated invariant chain; MHC HLA DR gamma chain; p33; HLA-DR-gamma; MHC HLA-DR gamma chain; Ia-associated invariant chain; HLA-DR antigens-associated invariant chain; CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated); II; DHLAG; HLADG; Ia-GAMMA; FLJ98970;